Background And Objective: Relative effectiveness of smoking cessation medications-varenicline, bupropion and nicotine replacement therapy (NRT)-remains unclear among smokers in real-world settings. Evidence in females and smokers with light/moderate nicotine dependence is particularly insufficient. This study compared the effectiveness of varenicline, bupropion or NRT gum relative to NRT patch, in achieving abstinence among recent quitters.

Methods: In a national smoking cessation program in Taiwan (2012-2015), a cohort of 11,968 participants received varenicline (n = 5,052), bupropion (n = 823), NRT gum (n = 1944) or NRT patch (n = 4,149). The 7-day, 1-month or 6-month point-prevalence was calculated based on self-reported last smoking event via telephone interview after 6 months. Logistic regression modellings estimated odds ratios (OR) and 95% confidence intervals (CI) for achieving abstinence using different modalities (NRT patch as referent). Models included age, sex, education, marital status, geographic region, smoke-years, nicotine-dependence level, medical institution, number of clinic visits and medication use duration. Analyses were further stratified by sex and dependence severity.

Results: Participants were predominantly male (83%) with a mean age of 43.7±12.6 years. Varenicline users were more likely than NRT patch users to achieve abstinence, based on 7-day point-prevalence (OR = 1.30, CI: 1.19-1.44), 1-month point-prevalence (OR = 1.36, CI: 1.24-1.50) or 6-month point-prevalence (OR = 1.30, CI: 1.14-1.47). Compared with NRT patch, varenicline was associated with greater odds of being abstinent in women (OR = 1.29, CI: 1.01-1.65), men (OR = 1.31, CI: 1.18-1.46), those with light/moderate dependence (OR = 1.42, CI: 1.24-1.63) or smokers with severe dependence (OR = 1.19, CI: 1.04-1.37), based on 7-day point-prevalence. Differences in effectiveness were not observed between users of bupropion, NRT gum and NRT patch.

Conclusions: In smoking cessation clinics in Taiwan, varenicline users reported higher abstinence rates than NRT patch users after 6 months. Women and smokers with light/moderate nicotine dependence may also benefit from varenicline in actual clinical practice.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125644PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0166992PLOS

Publication Analysis

Top Keywords

nrt patch
24
smoking cessation
16
nrt gum
12
nrt
10
effectiveness smoking
8
smokers light/moderate
8
light/moderate nicotine
8
nicotine dependence
8
bupropion nrt
8
achieving abstinence
8

Similar Publications

Objective: The purpose of this study was to evaluate the efficacy of combination nicotine replacement therapy (c-NRT) for smoking cessation among people with HIV (PWH) in South Africa.

Design: We conducted an open label, individually randomized clinical trial.

Methods: Using a two-armed approach, PWH who smoke were randomized to receive either 1) intensive anti-smoking behavioral counseling (BC) or 2) intensive anti-smoking BC plus c-NRT (nicotine patches augmented by nicotine gum).

View Article and Find Full Text PDF

Effects of Varenicline, Bupropion, Nicotine Patch, and Placebo on Treating Smoking Among Persons With Current or Past Major Depressive Disorder: Secondary Analysis of a Double-Blind, Randomized, Placebo-Controlled Trial.

Am J Psychiatry

December 2024

Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston (Kypriotakis, Cinciripini, Minnix, Beneventi, Karam-Hage, Blalock); Department of Pediatrics, University of Texas Medical School at Houston (Green); Pfizer Inc., New York (Lawrence); Department of Psychiatry, University of California, San Diego, La Jolla (Anthenelli); Department of Psychiatry, University of Colorado, Aurora (Morris).

Objective: The aim of this study was to compare the safety and efficacy of the leading smoking cessation medications among individuals with current versus past major depressive disorder (MDD).

Methods: This was a secondary analysis of a randomized, double-blind trial over 12 weeks with varenicline or bupropion, followed by a 12-week assessment, in participants ages 18-75 with past (N=2,174) or current (N=451) MDD or without psychiatric disorders (N=4,028). Interventions included 12 weeks of pharmacotherapy with placebo, nicotine replacement therapy (NRT; nicotine patch), bupropion, or varenicline, and brief counseling.

View Article and Find Full Text PDF

Introduction: Concerns about potential side effects remain a barrier to uptake of Food and Drug Administration (FDA)-approved smoking cessation pharmacotherapy [i.e., varenicline, bupropion, nicotine replacement therapy (NRT)].

View Article and Find Full Text PDF
Article Synopsis
  • * Various smoking cessation methods exist, including nicotine replacement therapies and medications like varenicline and bupropion, with new options like cytisine and faster-acting NRTs being developed, enhancing choices for those trying to quit.
  • * Personalizing cessation strategies by assessing individual responses and preferences can lead to more effective treatment outcomes, including the potential use of combination therapies for those who need additional support.
View Article and Find Full Text PDF

Correlates of nicotine patch adherence in daily life.

Drug Alcohol Depend

January 2025

Center for Health Outcomes and Population Equity (HOPE), Huntsman Cancer Institute, University of Utah, USA; Department of Population Health Sciences, University of Utah, USA.

Background: African Americans who smoke are disproportionately affected by the health consequences of smoking. Nicotine replacement therapy (NRT) is effective for helping people successfully quit, yet there are well-documented issues with nicotine patch adherence. This study aimed to examine the real-time associations of risk factors for patch non-adherence [lapse, motivation, self-efficacy, urge, cigarette availability] with patch adherence in a sample of African Americans who smoke and are attempting to quit.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!